Figure 1:

CDK4/6 inhibitors decrease cell viability in IDH-mutant patient-derived glioma cell lines. A. Western blot of IDH-mutant glioma lines for p16, phosphorylated-Rb, IDH1 R132H mutation. Cyclophilin B serves as a loading control. B. Mutation profiles of IDH-mutant glioma lines. C. Relative cell viability of IDH-mutant glioma lines after exposure to abemaciclib at the indicated concentrations for 5 days. n = 6 for each concentration, bars ± SEM. D. Relative cell viability of IDH-mutant glioma lines after exposure to palbociclib at a dose of 1 μM for 5 days. n = 3–5 for each concentration, bars ± SEM. Comparisons based on unpaired t-test, ns: non-significant, **** p < 0.0001. E. Relative cell proliferation of IDH-mutant glioma lines after exposure to abemaciclib at the indicated concentration for 5 days. n = 6 for each concentration, bars ± SEM. Data in C, D and E are representative of at least three biological replicates.